Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients
The presence of the <i>JAK2-V617F</i> mutation, regardless of allele burden, and prior thrombosis were strongly associated with an increased risk of VTE. Patients with prefibrotic MF might be considered at high risk for developing ATE.
Authors
- Jenny Rinke (ORCID: https://orcid.org/0009-0006-7791-6561)
- Carl C. Crodel (ORCID: https://orcid.org/0009-0000-2160-1452)
- Andreas Hochhaus (ORCID: https://orcid.org/0000-0003-0626-0834)
- Manja Meggendorfer (ORCID: https://orcid.org/0000-0002-9038-3265)
- Constance Baer (ORCID: https://orcid.org/0000-0002-8571-1551)
- Ingrid Sander (ORCID: https://orcid.org/0000-0002-5014-4112)
- Aysun Tekbaş (ORCID: https://orcid.org/0000-0001-8993-2688)
- Thomas Ernst (ORCID: https://orcid.org/0000-0002-2170-9241)
- Olga Morath
Institutions
- Munich Leukemia Laboratory (Germany) (DE)
- Klinikum Magdeburg (DE)
- Jena University Hospital (DE)
Publication Details
- Journal
- Hämostaseologie
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1055/a-2410-8530
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.44